Long-Term Persistence of COVID-Induced Hyperglycemia: A Cohort Study.

Publication date: Feb 13, 2024

Although the short-term mortality of patients with COVID-19 infection and hyperglycemia has been well documented, there is little available data regarding longer-term prognosis. The presence of diabetes has not only influenced disease severity but has also impacted its transmission dynamics. In this study, we followed a historical cohort of patients without previous history of diabetes who presented with moderate to severe COVID-19 and were found to have hyperglycemia (random blood glucose > 140 mg/dL) at the time of admission. We evaluated the need for antidiabetic therapy in these patients at the end of 6 months and the risk factors associated with persistent hyperglycemia determined by monthly values of self-monitored blood glucose. Of the seventy participants who were followed telephonically, 54 (77%) continued to receive antidiabetic therapy or have persistent hyperglycemia (> 140 mg/dL) at the end of 6 months. Persistent hyperglycemia at the end of follow-up, was found to be associated with a higher blood glucose at presentation.

Concepts Keywords
Covid Antidiabetic
Diabetes Blood
Glucose Cohort
Monthly Covid
Therapy Diabetes


Type Source Name
disease MESH Hyperglycemia
disease MESH COVID-19
disease MESH infection
disease IDO history
disease IDO blood
drug DRUGBANK Dextrose unspecified form
disease VO time
disease VO monthly

Original Article

(Visited 1 times, 1 visits today)